Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The US FDA Reverses Decision And Allows Oxitriptan Compounding For Now

Executive Summary

The US FDA says new information brought to light by pharmacists and caregivers on compounded oxitriptan prompted the agency to reconsider its decision to exclude the substance from the 503A bulks list. Oxitriptan was placed on the do not compound list in February.

Advertisement

Related Content

No Means No, US FDA Advises 503A Compounding Pharmacies
FDA Final Rule Places Six Substances On 503A Bulks List; Rejects Four

Topics

Advertisement
UsernamePublicRestriction

Register

PS125601

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel